Bridging the scientific field and communities where research happens
HIV prevention research and development is accelerating, with more options available than ever before. But progress toward crucial targets to end the epidemic and prepare for future ones has been far too slow. New leadership, research, and commitments at the global, national, and local levels bring power and potential to strengthen and advance HIV prevention and global health equity, however, but we need to ensure that new policies and product access initiatives are inclusive and donors and decision makers are accountable.
AVAC tracks important issues, in research, policy, financing, news headlines and more. With colleagues and partners, we analyze the data, issues, policy and perspectives, and we translate it into useful and usable resources that all can use to inform their work. We do this by:
AVAC is tracking the impacts and consequences of the new US administration actions to dismantle foreign aid and the retreat from the US’ commitments to science and global health.
podcast
This episode features Merck Distinguished Scientist Rebeca Plank and AVAC’s Regional Manager for Research Engagement Grace Kumwenda. They explain why a monthly pill could be so important to HIV prevention and how GPP is shaping the design and rollout of the trials.
factsheet
The announcements on 9 July 2025 from Global Fund and Gilead about their next steps for injectable lenacapavir (LEN) for PrEP are welcome, as one more part of the process. But they raise as many questions as they answer. This brief summary is intended to help outline what is actually known–and not—and what needs to happen next.
report
This issue of PxWire looks at the scale of shuttered prevention programs for key populations, the potential market for injectable LEN, and the devastating cuts to research for an HIV vaccine.
To reach the UNAIDS target of 10 million PrEP users by 2025, initiations of oral PrEP alone will not be enough—and this graphic shows that the field is beginning to apply past lessons to accelerate introduction of injectable cabotegravir.
Linking journalists with researchers, civil society, policy makers and regulators for accurate and insightful reporting on HIV, COVID and global health equity.
A one-stop online clearinghouse for resources and information to help the global community effectively deliver proven methods of PrEP to everyone who needs it.
Tracking investments and funding trends in HIV prevention and cure R&D.
The US government shutdown that began at midnight on October 1 has stalled key public health operations just as the Supreme Court issued a ruling in AVAC v. Department of State that allowed $4 billion dollars in foreign aid to expire, eroding both health and human services and constitutional checks and balances. Meanwhile, Jeanne Marrazzo was officially fired as Director of NIAID, underscoring how politically motivated attacks on science are dismantling the infrastructure that has underpinned decades of progress in HIV prevention and research.
The stakes are high as the US approaches the start of a new fiscal year (FY26) on October 1, currently mired in stalled White House negotiations and a looming government shutdown; the Supreme Court’s pending decision on AVAC’s lawsuit; and the new US “America First” strategy to reshape foreign aid. This issue highlights major global health developments at the UN General Assembly, from debate over the future of UNAIDS to commitments from the Gates Foundation and Unitaid to accelerate access to injectable lenacapavir for PrEP (LEN), alongside new discussions on AI ethics and health.
AVAC welcomes parallel announcements from the Gates Foundation and Unitaid on strategic investments to accelerate the development of, access to and price reduction for generic versions of injectable lenacapavir (LEN), the highly effective six-monthly injection for HIV PrEP.